Atopic Dermatitis Diagnosis via Gene Expression RNA Panel
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnosis and treatment monitoring of atopic dermatitis (AD) rely heavily on clinical experience and lack specific laboratory tests, leading to inefficiencies and human error, with a need for improved molecular diagnostic tools to accurately assess treatment responses.
Innovation Solution
A gene panel comprising specific genes (SERPINB4, AKR1B10, S100A7, DEFB4A, RRM2, CCL18, etc.) is used for molecular diagnosis and treatment monitoring, involving skin biopsies to determine RNA expression levels and compare them to reference samples, with therapeutic agents like corticosteroids, dupilumab, and narrow-band UVB being administered based on gene expression profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If clinical experience-based diagnosis and monitoring methods are used, then treatment decisions can be made without specialized equipment, but diagnostic accuracy and treatment monitoring precision are reduced due to human error and lack of standardization
Solution Approach 1:
The patent replaces manual clinical assessment (mechanical/physical examination) with molecular biology-based detection methods. Specifically, it uses RNA expression analysis through techniques like qRT-PCR to objectively measure disease state and treatment response, substituting subjective clinical judgment with quantifiable molecular data that eliminates human error and provides standardized results
Solution Approach 2:
The patent introduces gene expression profiles as an intermediary between clinical observation and treatment decision-making. By measuring RNA expression levels of specific genes (e.g., S100A7, DEFB4A, LCE2B), the method creates an objective molecular marker system that mediates the diagnosis and monitoring process, providing standardized, reproducible data that bridges clinical practice and precision medicine
2Adaptability or versatility
If multiple severity scoring scales are used by different clinicians, then individual clinical assessments can be made, but treatment monitoring consistency and comparability are reduced
Solution Approach 1:
The patent changes the measurement parameter from subjective clinical scoring (EASI, SCORAD, POEM scales) to objective molecular parameters (RNA expression levels of specific genes). This parameter change enables consistent, standardized measurement across different clinicians and settings while maintaining the ability to assess various aspects of disease severity and treatment response through a unified molecular framework
3Productivity
If traditional diagnosis methods are used, then no specialized laboratory equipment is required, but time consumption increases due to reliance on clinician experience and manual assessment
Solution Approach 1:
The patent performs preliminary molecular characterization by establishing gene expression profiles that define AD disease state and treatment response patterns. By pre-identifying key genes (S100A7, DEFB4A, LCE2B, etc.) and their expression patterns, the method creates a standardized assay protocol that can be rapidly applied to patient samples, eliminating the need for time-consuming manual clinical assessment while maintaining high diagnostic efficiency
Data Source
AI summary
Provided herein is a method of diagnosing and treating a subject suffering from atopic dermatitis (AD), the method comprising: (a) obtaining a skin biopsy from a subject suspected of suffering from AD; (b) determining a level of RNA expression in the skin biopsy of genes selected from the 89ADGES gene panel; (c) comparing the determined level of RNA expression of the selected genes to the level of RNA expression of the selected genes in a reference sample comprising RNA expression products from normal healthy skin cells; (d) diagnosing the subject as suffering from AD when specific genes are up-regulated compared to the reference sample and when specific genes are down-regulated compared to the reference sample; and (e) treating the subject with a therapy effective for the treatment of AD. Methods of managing treatment of a subject suffering from AD are also provided.